Dr. Castillo on the CLOVER-WaM Trial in Waldenström Macroglobulinemia

Jorge J. Castillo, MD, associate professor of medicine, Harvard Medical School, clinical director, senior physician, Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, discusses the phase 2 CLOVER WaM trial (NCT02952508) in Waldenström macroglobulinemia (WM).

CLOVER-WaM is the pivotal expansion portion of the CLOVER-1 trial, which investigated the small-molecule radiotherapeutic iopofosine I-131 (CLR 131) in patients with select B-cell malignancies, including WM. 

CLOVER-WaM will enroll patients who have received at least 2 prior lines of therapy with exposure to a BTK inhibitor, and the trial will feature a population without many treatment options remaining, Castillo says. 

Unlike other treatments for WM, iopofosine I-131 has demonstrated central nervous system (CNS) penetration, Castillo adds. Patients with WM with CNS involvement have typically been excluded from past clinical trials, and CLOVER-WaM represents the chance to include this specific subset of patients, Castillo concludes.